| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Unknown; the target of this analog has not been identified. The parent Pimelic Diphenylamide 106 is a class I HDAC inhibitor, but this analog's activity may differ. It is assumed to potentially interact with HDACs (HDAC1, HDAC2, HDAC3), but this remains unconfirmed.
|
|---|---|
| ln Vitro |
No in vitro activity data is reported. As an analog with unknown activity, it may be inactive or weakly active against HDACs. It is used as a negative control or for SAR studies to identify structural features critical for HDAC inhibition. Activity would need to be determined experimentally.
|
| ln Vivo |
No in vivo activity data is available. Without established in vitro activity, in vivo studies are not warranted. The compound is not intended for therapeutic evaluation; it is a research chemical for exploratory studies.
|
| Enzyme Assay |
The compound is supplied as a solid and can be dissolved in DMSO for biochemical assays. To test HDAC inhibitory activity, a typical protocol uses a fluorometric HDAC assay kit. Varying concentrations of the analog (0.01-100 microM) are incubated with recombinant HDAC1 (50 ng) in assay buffer for 30 minutes at 37degC. A fluorogenic substrate (acetylated peptide) is added, and the reaction is stopped after 30 minutes. Fluorescence is measured (excitation 360 nm, emission 460 nm). IC50 is calculated relative to a reference inhibitor (e.g., trichostatin A).
|
| Cell Assay |
No in vitro cellular protocols are specific to this analog. For screening, cells (e.g., HeLa) are treated with the analog (1-50 microM) for 24-48 hours. Acetylation of histones H3 and H4 is detected by Western blotting using anti‑acetyl‑lysine antibodies. Cell cycle distribution is analyzed by flow cytometry after propidium iodide staining. Cytotoxicity is measured by MTT. However, no such data is publicly available for this analog.
|
| Animal Protocol |
No animal studies have been reported for this analog. If in vitro activity is confirmed, a typical in vivo protocol for an HDAC inhibitor would involve intraperitoneal administration (50-100 mg/kg) in mice bearing tumor xenografts, with monitoring of tumor volume and acetylation markers in peripheral blood mononuclear cells. For this analog, such studies have not been conducted.
|
| ADME/Pharmacokinetics |
No PK data is available. The analog (pimelic diphenylamide) is similar to known HDAC inhibitors that generally have moderate oral bioavailability, a short half‑life (1-4 hours), and extensive liver metabolism (glucuronidation, oxidation). However, this analog's PK profile is unknown.
|
| Toxicity/Toxicokinetics |
No toxicity data is available. The parent compound, pimelic diphenylamide 106, has not been extensively tested for toxicity. As an analog, no safety data is available. Standard safety precautions should be used when handling; it is intended for research use only and not for human consumption.
|
| References |
[1]. Chou CJ, et al. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem. 2008 Dec 19;283(51):35402-35409.
[2]. Xu C, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol. 2009 Sep 25;16(9):980-989. |
| Additional Infomation |
Pimelic Diphenylamide 106 analog is also known as RGFA-8 analog and TC-H 106 analog. Its exact IUPAC name is N1-(2-aminophenyl)-N8-(p-tolyl)octanediamide. It is a pimelic acid derivative with two phenylamide groups. The analog has unknown biological activity and is primarily used as a research chemical. It is not approved for clinical use. Molecular formula: C21H27N3O2; molecular weight: 353.46.
|
| Molecular Formula |
C21H27N3O2
|
|---|---|
| Molecular Weight |
353.46
|
| Exact Mass |
353.21
|
| CAS # |
2070015-24-4
|
| Related CAS # |
Pimelic Diphenylamide 106;937039-45-7
|
| PubChem CID |
118704757
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NC2=CC=CC=C2N
|
| InChi Key |
NTVVDUQLJHPXJY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H27N3O2/c1-16-12-14-17(15-13-16)23-20(25)10-4-2-3-5-11-21(26)24-19-9-7-6-8-18(19)22/h6-9,12-15H,2-5,10-11,22H2,1H3,(H,23,25)(H,24,26)
|
| Chemical Name |
N'-(2-aminophenyl)-N-(4-methylphenyl)octanediamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 30 mg/mL (84.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8292 mL | 14.1459 mL | 28.2917 mL | |
| 5 mM | 0.5658 mL | 2.8292 mL | 5.6583 mL | |
| 10 mM | 0.2829 mL | 1.4146 mL | 2.8292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
